Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates

Jayson Rakesh Baman; Joseph Knapper; Zankhana Raval; Matthew E. Harinstein; John J. Friedewald; Kameswari Maganti; Michael J. Cuttica; Michael I. Abecassis; Ziad A. Ali; Mihai Gheorghiade; James D. Flaherty

doi:10.2215/CJN.03640319

Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates

Jayson Rakesh Baman, Joseph Knapper, Zankhana Raval, Matthew E. Harinstein, John J. Friedewald, Kameswari Maganti, Michael J. Cuttica, Michael I. Abecassis, Ziad A. Ali, Mihai Gheorghiade, James D. Flaherty

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The pretransplant risk assessment for patients with ESKD who are undergoing evaluation for kidney transplant is complex and multifaceted. When considering cardiovascular disease in particular, many factors should be considered. Given the increasing incidence of kidney transplantation and the growing body of evidence addressing ESKD-specific cardiovascular risk profiles, there is an important need for a consolidated, evidence-based model that considers the unique cardiovascular challenges that these patients face. Cardiovascular physiology is altered in these patients by abrupt shifts in volume status, altered calcium-phosphate metabolism, high-output states (in the setting of arteriovenous fistulization), and adverse geometric and electrical remodeling, to name a few. Here, we present a contemporary review by addressing cardiomyopathy/heart failure, pulmonary hypertension, valvular dysfunction, and arrhythmia/sudden cardiac death within the ESKD population.

Original language	English (US)
Pages (from-to)	1670-1676
Number of pages	7
Journal	Clinical Journal of the American Society of Nephrology
Volume	14
Issue number	11
DOIs	https://doi.org/10.2215/CJN.03640319
State	Published - Nov 7 2019

Bibliographical note

Funding Information:
Dr. Ali reports grants from Abbott Vascular and Cardiovascular Systems Inc.; personal fees from Acist Medical, AstraZeneca, Boston Scientific, Cardinal Health, and Opsens Medical; and personal and other fees such as stock from Shockwave Medical, outside the submitted work. Dr. Cuttica reports grants for clinical trials, personal fees from speaker bureaus and advisory board consulting, and nonfinancial support from Actelion and United Therapeutics; grants for clinical trials, personal fees from speaker bureaus and advisory board consulting, and nonfinancial support from Bayer and Gilead; and a clinical trial grant from Reata Pharmaceuticals, outside of the submitted work. Dr. Friedewald reports grants and personal fees from AbbVie; personal fees from American Society of Nephrology; personal fees from Novartis; personal fees from Sanofi; grants from Shire; grants, personal fees, and other fees including equity interest from Transplant Genomics, Inc.; grants from Vaiteris; and personal fees from Viela Bio, outside the submitted work. Dr. Abecassis, Dr. Baman, Dr. Flaherty, Dr. Harinstein, Dr. Knapper, Dr. Maganti, and Dr. Raval have nothing to disclose.

Publisher Copyright:
© 2019, American Society of Nephrology. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.2215/CJN.03640319

OpenUrl availability

Full text

Cite this

Baman, J. R., Knapper, J., Raval, Z., Harinstein, M. E., Friedewald, J. J., Maganti, K., Cuttica, M. J., Abecassis, M. I., Ali, Z. A., Gheorghiade, M., & Flaherty, J. D. (2019). Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates. Clinical Journal of the American Society of Nephrology, 14(11), 1670-1676. https://doi.org/10.2215/CJN.03640319

Baman, JR, Knapper, J, Raval, Z, Harinstein, ME, Friedewald, JJ, Maganti, K, Cuttica, MJ, Abecassis, MI, Ali, ZA, Gheorghiade, M & Flaherty, JD 2019, 'Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates', Clinical Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 1670-1676. https://doi.org/10.2215/CJN.03640319

@article{17f5ef88e6c145b0b2aa2a8f028fb759,

title = "Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates",

abstract = "The pretransplant risk assessment for patients with ESKD who are undergoing evaluation for kidney transplant is complex and multifaceted. When considering cardiovascular disease in particular, many factors should be considered. Given the increasing incidence of kidney transplantation and the growing body of evidence addressing ESKD-specific cardiovascular risk profiles, there is an important need for a consolidated, evidence-based model that considers the unique cardiovascular challenges that these patients face. Cardiovascular physiology is altered in these patients by abrupt shifts in volume status, altered calcium-phosphate metabolism, high-output states (in the setting of arteriovenous fistulization), and adverse geometric and electrical remodeling, to name a few. Here, we present a contemporary review by addressing cardiomyopathy/heart failure, pulmonary hypertension, valvular dysfunction, and arrhythmia/sudden cardiac death within the ESKD population.",

author = "Baman, {Jayson Rakesh} and Joseph Knapper and Zankhana Raval and Harinstein, {Matthew E.} and Friedewald, {John J.} and Kameswari Maganti and Cuttica, {Michael J.} and Abecassis, {Michael I.} and Ali, {Ziad A.} and Mihai Gheorghiade and Flaherty, {James D.}",

note = "Funding Information: Dr. Ali reports grants from Abbott Vascular and Cardiovascular Systems Inc.; personal fees from Acist Medical, AstraZeneca, Boston Scientific, Cardinal Health, and Opsens Medical; and personal and other fees such as stock from Shockwave Medical, outside the submitted work. Dr. Cuttica reports grants for clinical trials, personal fees from speaker bureaus and advisory board consulting, and nonfinancial support from Actelion and United Therapeutics; grants for clinical trials, personal fees from speaker bureaus and advisory board consulting, and nonfinancial support from Bayer and Gilead; and a clinical trial grant from Reata Pharmaceuticals, outside of the submitted work. Dr. Friedewald reports grants and personal fees from AbbVie; personal fees from American Society of Nephrology; personal fees from Novartis; personal fees from Sanofi; grants from Shire; grants, personal fees, and other fees including equity interest from Transplant Genomics, Inc.; grants from Vaiteris; and personal fees from Viela Bio, outside the submitted work. Dr. Abecassis, Dr. Baman, Dr. Flaherty, Dr. Harinstein, Dr. Knapper, Dr. Maganti, and Dr. Raval have nothing to disclose. Publisher Copyright: {\textcopyright} 2019, American Society of Nephrology. All rights reserved.",

year = "2019",

month = nov,

day = "7",

doi = "10.2215/CJN.03640319",

language = "English (US)",

volume = "14",

pages = "1670--1676",

journal = "Clinical Journal of the American Society of Nephrology",

issn = "1555-9041",

publisher = "American Society of Nephrology",

number = "11",

}

TY - JOUR

T1 - Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates

AU - Baman, Jayson Rakesh

AU - Knapper, Joseph

AU - Raval, Zankhana

AU - Harinstein, Matthew E.

AU - Friedewald, John J.

AU - Maganti, Kameswari

AU - Cuttica, Michael J.

AU - Abecassis, Michael I.

AU - Ali, Ziad A.

AU - Gheorghiade, Mihai

AU - Flaherty, James D.

N1 - Funding Information: Dr. Ali reports grants from Abbott Vascular and Cardiovascular Systems Inc.; personal fees from Acist Medical, AstraZeneca, Boston Scientific, Cardinal Health, and Opsens Medical; and personal and other fees such as stock from Shockwave Medical, outside the submitted work. Dr. Cuttica reports grants for clinical trials, personal fees from speaker bureaus and advisory board consulting, and nonfinancial support from Actelion and United Therapeutics; grants for clinical trials, personal fees from speaker bureaus and advisory board consulting, and nonfinancial support from Bayer and Gilead; and a clinical trial grant from Reata Pharmaceuticals, outside of the submitted work. Dr. Friedewald reports grants and personal fees from AbbVie; personal fees from American Society of Nephrology; personal fees from Novartis; personal fees from Sanofi; grants from Shire; grants, personal fees, and other fees including equity interest from Transplant Genomics, Inc.; grants from Vaiteris; and personal fees from Viela Bio, outside the submitted work. Dr. Abecassis, Dr. Baman, Dr. Flaherty, Dr. Harinstein, Dr. Knapper, Dr. Maganti, and Dr. Raval have nothing to disclose. Publisher Copyright: © 2019, American Society of Nephrology. All rights reserved.

PY - 2019/11/7

Y1 - 2019/11/7

N2 - The pretransplant risk assessment for patients with ESKD who are undergoing evaluation for kidney transplant is complex and multifaceted. When considering cardiovascular disease in particular, many factors should be considered. Given the increasing incidence of kidney transplantation and the growing body of evidence addressing ESKD-specific cardiovascular risk profiles, there is an important need for a consolidated, evidence-based model that considers the unique cardiovascular challenges that these patients face. Cardiovascular physiology is altered in these patients by abrupt shifts in volume status, altered calcium-phosphate metabolism, high-output states (in the setting of arteriovenous fistulization), and adverse geometric and electrical remodeling, to name a few. Here, we present a contemporary review by addressing cardiomyopathy/heart failure, pulmonary hypertension, valvular dysfunction, and arrhythmia/sudden cardiac death within the ESKD population.

AB - The pretransplant risk assessment for patients with ESKD who are undergoing evaluation for kidney transplant is complex and multifaceted. When considering cardiovascular disease in particular, many factors should be considered. Given the increasing incidence of kidney transplantation and the growing body of evidence addressing ESKD-specific cardiovascular risk profiles, there is an important need for a consolidated, evidence-based model that considers the unique cardiovascular challenges that these patients face. Cardiovascular physiology is altered in these patients by abrupt shifts in volume status, altered calcium-phosphate metabolism, high-output states (in the setting of arteriovenous fistulization), and adverse geometric and electrical remodeling, to name a few. Here, we present a contemporary review by addressing cardiomyopathy/heart failure, pulmonary hypertension, valvular dysfunction, and arrhythmia/sudden cardiac death within the ESKD population.

UR - http://www.scopus.com/inward/record.url?scp=85074676701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074676701&partnerID=8YFLogxK

U2 - 10.2215/CJN.03640319

DO - 10.2215/CJN.03640319

M3 - Article

C2 - 31554619

AN - SCOPUS:85074676701

SN - 1555-9041

VL - 14

SP - 1670

EP - 1676

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

IS - 11

ER -

Preoperative noncoronary cardiovascular assessment and management of kidney transplant candidates

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this